Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
7 p, 549.5 KB Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma / Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ; Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ; Escudier, Bernard (Gustave Roussy) ; Pal, Sumanta (City of Hope National Medical Center) ; Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ; Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ; Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ; Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ; Park, Se Hoon (Samsung Medical Center) ; Geertsen, Poul F. (Copenhagen University Hospital) ; Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ; Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ; Markby, David W. (Exelixis, Inc) ; Arroyo, Alan (Exelixis, Inc) ; Dean, Mark (Exelixis, Inc) ; Choueiri, Toni K. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; George, Daniel (Duke University Medical Center) ; Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.